Market Place
Sourcing Support
Acelyrin Founder Joins Cue In Latest China Licensing Deal
01 May 2026 //
ENDPOINTS
Cue Bio Appoints Shao-Lee Lin, MD, PhD, as CEO
30 Apr 2026 //
GLOBENEWSWIRE
Cue Bio To Unveil Preclinical Data On Autoimmune Drug CUE-401
15 Apr 2026 //
FIRSTWORD PHARMA
Cue Bio to Receive $7.5M Milestone From Boehringer
08 Apr 2026 //
GLOBENEWSWIRE
Cue Bio Appoints Lucinda Warren As CFO & Business Officer
12 Feb 2026 //
GLOBENEWSWIRE
Cue Bio: Leadership Transition To Drive Growth In Therapies
29 Sep 2025 //
GLOBENEWSWIRE
Cue Biopharma Joins Chat at Cantor Global Healthcare Conference
21 Aug 2025 //
GLOBENEWSWIRE
Cue Biopharma Begins Trial of CUE-102 in Recurrent Glioblastoma
13 Aug 2025 //
GLOBENEWSWIRE
Cue Biopharma Q2 2025 Financial Results and Business Highlights
12 Aug 2025 //
GLOBENEWSWIRE
Cue Biopharma Reports Q1 2025 Financial Results & Highlights
12 May 2025 //
GLOBENEWSWIRE
Cue Biopharma to Join Fireside Chat at Citizens Conference
05 May 2025 //
GLOBENEWSWIRE
Cue Biopharma to Host Business Update Call and Webcast
14 Apr 2025 //
GLOBENEWSWIRE
Cue Biopharma Announces Proposed Public Offering
14 Apr 2025 //
GLOBENEWSWIRE
Cue Biopharma Reports Q4 and Full Year 2024 Financial Results
31 Mar 2025 //
GLOBENEWSWIRE
Cue Biopharma Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
29 Nov 2024 //
GLOBENEWSWIRE
Cue Bio to Join Discussion at Piper Sandler Healthcare Conference
25 Nov 2024 //
GLOBENEWSWIRE
Cue Biopharma Reports Q3 2024 Financial Results & Highlights
14 Nov 2024 //
GLOBENEWSWIRE
Cue Biopharma Joins Fireside Chat at Stifel 2024 Conference
12 Nov 2024 //
GLOBENEWSWIRE
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
03 Sep 2024 //
GLOBENEWSWIRE
Cue Cuts 25% Jobs, Focuses On Preclinical Over Clinical-Stage Assets
26 Jul 2024 //
FIERCE BIOTECH
Cue Biopharma Prioritizes Autoimmune Programs, Optimizes Workforce
25 Jul 2024 //
GLOBENEWSWIRE
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
22 Nov 2023 //
GLOBENEWSWIRE
Cue Bio to Present at Three Upcoming Investor Healthcare Conferences in November
07 Nov 2023 //
GLOBENEWSWIRE
Cue Biopharma to Host Business Update Call and Webcast
02 Nov 2023 //
GLOBENEWSWIRE
Cue Biopharma to Present at the 2023(ASCO) Annual Meeting
15 May 2023 //
GLOBENEWSWIRE
Cue Biopharma Reports1Q 2023 FYR and Recent Business Highlights
09 May 2023 //
GLOBENEWSWIRE
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive
25 Apr 2023 //
GLOBENEWSWIRE
Cue Biopharma Welcomes Mr. Patrick Verheyen to Board of Directors
12 Apr 2023 //
GLOBENEWSWIRE
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results
21 Mar 2023 //
GLOBENEWSWIRE
Cue Biopharma to Host Business Update Call and Webcast
15 Mar 2023 //
GLOBENEWSWIRE
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
01 Mar 2023 //
GLOBENEWSWIRE
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to Advisory Board
16 Feb 2023 //
GLOBENEWSWIRE
Cue Biopharma to Present at Two February 2023 Scientific Conferences
01 Feb 2023 //
GLOBENEWSWIRE
Cue Biopharma Announces Chief Medical Officer Transition
23 Jan 2023 //
GLOBENEWSWIRE
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
22 Nov 2022 //
GLOBENEWSWIRE
Cue Biopharma Announces $30 M Private Investment in Public Equity Financing
14 Nov 2022 //
GLOBENEWSWIRE
Cue Biopharma Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101
10 Nov 2022 //
GLOBENEWSWIRE
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in Nov
09 Nov 2022 //
GLOBENEWSWIRE
Cue Biopharma Announces Upcoming Scientific Presentations at the’s (SITC)
05 Oct 2022 //
GLOBENEWSWIRE
Cue Biopharma Granted FDA Fast Track Designation for CUE-101
04 Oct 2022 //
GLOBENEWSWIRE
Cue Biopharma to Present at Two September 2022 Scientific Conferences
07 Sep 2022 //
GLOBENEWSWIRE
Cue Biopharma begins patient dosing in phase 1 study of CUE-102
24 Aug 2022 //
PHARMABIZ
Cue Biopharma doses first subject in Phase I trial of WT1-expressing cancers
23 Aug 2022 //
CLINICALTRIALSARENA
Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102
22 Aug 2022 //
GLOBENEWSWIRE
Cue Biopharma Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
11 Jul 2022 //
GLOBENEWSWIRE
Cue Biopharma to Present at the Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Cue Biopharma to Present at the 2022 ASCO
26 May 2022 //
GLOBENEWSWIRE
LG Chem’s US partner starts phase 1 WT-1 targeting cancer drug study
12 May 2022 //
KOREABIOMED
Cue Biopharma Receives FDA Acceptance of IND Application for CUE-102
11 May 2022 //
GLOBENEWSWIRE
Cue Biopharma Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Cue Biopharma to Present at Upcoming Oppenheimer 32nd Annual Conference
10 Mar 2022 //
GLOBENEWSWIRE
Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform
02 Mar 2022 //
GLOBENEWSWIRE
Cue Biopharma Reports Two Objective Responses in First Interim Update
26 Jan 2022 //
GLOBENEWSWIRE
Cue Biopharma to Host Call and Webcast for Ongoing CUE-101 Clinical Trials
20 Jan 2022 //
GLOBENEWSWIRE
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference
22 Nov 2021 //
GLOBENEWSWIRE
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
10 Nov 2021 //
GLOBENEWSWIRE
Cue Announces Publication in The Journal of Clinical Investigation Highlighting
21 Oct 2021 //
GLOBENEWSWIRE
Cue Biopharma Announces Upcoming Scientific Presentations at the Society
04 Oct 2021 //
GLOBENEWSWIRE
